Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: A New CEO at Quanterix; VP at Biodesix; and More

Premium

Quanterix announced this week it has appointed Paul Chapman as its new president and CEO, replacing Martin Madaus, who will continue at the company as executive chairman.

Chapman was previously vice president of EMD Millipore's BioPharm Processing Solutions business. Before that he was vice president of hospital solutions for Roche Near Patient Testing in Austria.


Biodesix this week appointed Dominic Spinella vice president of clinical development and medical affairs.

Spinella was previously executive director and head of translational and molecular medicine for Pfizer's biotherapeutics division. Prior to that he was head of translational medicine for Pfizer Oncology as well as vice president of exploratory research at Chugai Pharmaceuticals.


Opko Health has appointed Juan Rodriguez as senior vice president and chief financial officer.

Rodriguez was previously a consultant to software firm Cognitec Systems. Before that he held a number of executive positions at Kos Pharmaceuticals, which was acquired in 2007 by Abbott Laboratories.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.